Previously, we investigated the proteomic profiles of open biopsy samples obtained from osteosarcoma patients before chemotherapy and identified peroxiredoxin 2 (PRDX2) as a novel predictive biomarker with response to induction chemotherapy with ifosfamide, doxorubicin, and cisplatin [20]. The gene discussed is PRDX2; the disease is osteosarcoma.